Canbex Therapeutics Ltd.
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.canbex.co.uk
Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis
Phase 2
Completed
- Conditions
- Spasticity in People With Multiple Sclerosis
- Interventions
- Drug: VSN16ROther: Placebo
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Canbex Therapeutics Ltd
- Target Recruit Count
- 160
- Registration Number
- NCT02542787
- Locations
- π¬π§
The Neuroscience Research Centre, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom
π¬π§The National Hospital for Neurology and Neurosurgery, London, United Kingdom
π¬π§The Royal London Hospital, London, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath